Local delivery of a carbohydrate analog for reducing arthritic inflammation and rebuilding cartilage

Chaekyu Kim, Ok Hee Jeon, Do Hun Kim, J. Jeremy Chae, Lucas Shores, Nicholas Bernstein, Rahul Bhattacharya, Jeannine M. Coburn, Kevin J Yarema, Jennifer Hartt Elisseeff

Research output: Contribution to journalArticle

Abstract

Osteoarthritis (OA) is a degenerative joint disease characterized by articular cartilage degradation. Because OA has a multifactorial nature and complex interrelationship of the individual elements of a whole joint, there is a need for comprehensive therapeutic approaches for cartilage tissue engineering, which simultaneously address multiple aspects of disease etiology. In this work, we investigated a multifunctional carbohydrate-based drug candidate, tri-butanoylated N-acetyl-d-galactosamine analog (3,4,6-O-Bu3GalNAc) that induced cartilage tissue production by human mesenchymal stem cells (hMSCs) and human OA chondrocytes by modulating Wnt/β-catenin signaling activity. The dual effects promoted chondrogenesis of human MSC and reduced inflammation of human OA chondrocytes in in vitro cultures. Translating these findings in vivo, we evaluated therapeutic effect of 3,4,6-O-Bu3GalNAc on the rat model of posttraumatic OA when delivered via local intra-articular sustained-release delivery using microparticles and found this method to be efficacious in preventing OA progression. These results show that 3,4,6-O-Bu3GalNAc, a disease modifying OA drug candidate, has promising therapeutic potential for articular cartilage repair.

Original languageEnglish (US)
Pages (from-to)93-101
Number of pages9
JournalBiomaterials
Volume83
DOIs
StatePublished - Mar 1 2016

Fingerprint

Cartilage
Carbohydrates
Osteoarthritis
Arthritis
Inflammation
Galactosamine
Catenins
Articular Cartilage
Chondrocytes
Stem cells
Tissue engineering
Pharmaceutical Preparations
Rats
Repair
Joints
Tissue
Chondrogenesis
Degradation
Therapeutic Uses
Tissue Engineering

Keywords

  • Carbohydrates
  • Disease-modifying OA drug
  • Drug delivery
  • Mesenchymal stem cells
  • Osteoarthritis
  • Tissue engineering

ASJC Scopus subject areas

  • Biomaterials
  • Bioengineering
  • Ceramics and Composites
  • Mechanics of Materials
  • Biophysics

Cite this

Local delivery of a carbohydrate analog for reducing arthritic inflammation and rebuilding cartilage. / Kim, Chaekyu; Jeon, Ok Hee; Kim, Do Hun; Chae, J. Jeremy; Shores, Lucas; Bernstein, Nicholas; Bhattacharya, Rahul; Coburn, Jeannine M.; Yarema, Kevin J; Elisseeff, Jennifer Hartt.

In: Biomaterials, Vol. 83, 01.03.2016, p. 93-101.

Research output: Contribution to journalArticle

Kim, Chaekyu ; Jeon, Ok Hee ; Kim, Do Hun ; Chae, J. Jeremy ; Shores, Lucas ; Bernstein, Nicholas ; Bhattacharya, Rahul ; Coburn, Jeannine M. ; Yarema, Kevin J ; Elisseeff, Jennifer Hartt. / Local delivery of a carbohydrate analog for reducing arthritic inflammation and rebuilding cartilage. In: Biomaterials. 2016 ; Vol. 83. pp. 93-101.
@article{e14149b0174542a58e9f80aaf5f29f1b,
title = "Local delivery of a carbohydrate analog for reducing arthritic inflammation and rebuilding cartilage",
abstract = "Osteoarthritis (OA) is a degenerative joint disease characterized by articular cartilage degradation. Because OA has a multifactorial nature and complex interrelationship of the individual elements of a whole joint, there is a need for comprehensive therapeutic approaches for cartilage tissue engineering, which simultaneously address multiple aspects of disease etiology. In this work, we investigated a multifunctional carbohydrate-based drug candidate, tri-butanoylated N-acetyl-d-galactosamine analog (3,4,6-O-Bu3GalNAc) that induced cartilage tissue production by human mesenchymal stem cells (hMSCs) and human OA chondrocytes by modulating Wnt/β-catenin signaling activity. The dual effects promoted chondrogenesis of human MSC and reduced inflammation of human OA chondrocytes in in vitro cultures. Translating these findings in vivo, we evaluated therapeutic effect of 3,4,6-O-Bu3GalNAc on the rat model of posttraumatic OA when delivered via local intra-articular sustained-release delivery using microparticles and found this method to be efficacious in preventing OA progression. These results show that 3,4,6-O-Bu3GalNAc, a disease modifying OA drug candidate, has promising therapeutic potential for articular cartilage repair.",
keywords = "Carbohydrates, Disease-modifying OA drug, Drug delivery, Mesenchymal stem cells, Osteoarthritis, Tissue engineering",
author = "Chaekyu Kim and Jeon, {Ok Hee} and Kim, {Do Hun} and Chae, {J. Jeremy} and Lucas Shores and Nicholas Bernstein and Rahul Bhattacharya and Coburn, {Jeannine M.} and Yarema, {Kevin J} and Elisseeff, {Jennifer Hartt}",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.biomaterials.2015.12.029",
language = "English (US)",
volume = "83",
pages = "93--101",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Local delivery of a carbohydrate analog for reducing arthritic inflammation and rebuilding cartilage

AU - Kim, Chaekyu

AU - Jeon, Ok Hee

AU - Kim, Do Hun

AU - Chae, J. Jeremy

AU - Shores, Lucas

AU - Bernstein, Nicholas

AU - Bhattacharya, Rahul

AU - Coburn, Jeannine M.

AU - Yarema, Kevin J

AU - Elisseeff, Jennifer Hartt

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Osteoarthritis (OA) is a degenerative joint disease characterized by articular cartilage degradation. Because OA has a multifactorial nature and complex interrelationship of the individual elements of a whole joint, there is a need for comprehensive therapeutic approaches for cartilage tissue engineering, which simultaneously address multiple aspects of disease etiology. In this work, we investigated a multifunctional carbohydrate-based drug candidate, tri-butanoylated N-acetyl-d-galactosamine analog (3,4,6-O-Bu3GalNAc) that induced cartilage tissue production by human mesenchymal stem cells (hMSCs) and human OA chondrocytes by modulating Wnt/β-catenin signaling activity. The dual effects promoted chondrogenesis of human MSC and reduced inflammation of human OA chondrocytes in in vitro cultures. Translating these findings in vivo, we evaluated therapeutic effect of 3,4,6-O-Bu3GalNAc on the rat model of posttraumatic OA when delivered via local intra-articular sustained-release delivery using microparticles and found this method to be efficacious in preventing OA progression. These results show that 3,4,6-O-Bu3GalNAc, a disease modifying OA drug candidate, has promising therapeutic potential for articular cartilage repair.

AB - Osteoarthritis (OA) is a degenerative joint disease characterized by articular cartilage degradation. Because OA has a multifactorial nature and complex interrelationship of the individual elements of a whole joint, there is a need for comprehensive therapeutic approaches for cartilage tissue engineering, which simultaneously address multiple aspects of disease etiology. In this work, we investigated a multifunctional carbohydrate-based drug candidate, tri-butanoylated N-acetyl-d-galactosamine analog (3,4,6-O-Bu3GalNAc) that induced cartilage tissue production by human mesenchymal stem cells (hMSCs) and human OA chondrocytes by modulating Wnt/β-catenin signaling activity. The dual effects promoted chondrogenesis of human MSC and reduced inflammation of human OA chondrocytes in in vitro cultures. Translating these findings in vivo, we evaluated therapeutic effect of 3,4,6-O-Bu3GalNAc on the rat model of posttraumatic OA when delivered via local intra-articular sustained-release delivery using microparticles and found this method to be efficacious in preventing OA progression. These results show that 3,4,6-O-Bu3GalNAc, a disease modifying OA drug candidate, has promising therapeutic potential for articular cartilage repair.

KW - Carbohydrates

KW - Disease-modifying OA drug

KW - Drug delivery

KW - Mesenchymal stem cells

KW - Osteoarthritis

KW - Tissue engineering

UR - http://www.scopus.com/inward/record.url?scp=84958042680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958042680&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2015.12.029

DO - 10.1016/j.biomaterials.2015.12.029

M3 - Article

C2 - 26773662

AN - SCOPUS:84958042680

VL - 83

SP - 93

EP - 101

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

ER -